Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation
The purpose of this study is to evaluate time to progression (TTP) by PSA in patients with high risk prostate cancer after definitive therapy.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Taxotere
Phase: Phase 2
Ages Eligible For Study:
- Patients who have undergone a radical prostatectomy (should have unmeasurable PSA) or radiation therapy for prostate cancer and who have high risk disease as defined by one of the following: - Node positive disease post-operatively - Capsule involvement - Seminal Vesicles involvement - Gleason score ? 8 - >50% of core biopsies that are positive - Clinical Stage T2c and T3 - Pre-op PSA > 15 plus Gleason score of 7 - Age greater than 18 - ECOG Performance Status 0-1 - Serum creatinine <= 1.5 mg/dl - Granulocyte count >= 1500/m3, Hemoglobin > 8.0 g/dl, and platelet count >= 100,000/m3 - Total bilirubin <= ULN - AST, ALT and Alkaline Phosphatase must be within the range allowing for eligibility. - Signed patient informed consent. - Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for three months thereafter.